San Francisco startup Structure Therapeutics can be engaged on an oral, when-day by day GLP-one drug named GSBR-1290—the drug surpassed Wall Avenue’s expectations in June any time a mid-phase analyze confirmed normal weight loss of about 6% and it designs to start A different mid-stage demo to the top of the year—that founder and CEO Raymond